Compositions and methods for inhibiting adenylate cyclase 9 (ac9)
AssigneeInstitut de Cardiologie de Montreal
InventorsMathieu BRODEUR, David RHAINDS, Jean-Claude TARDIF
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of decreasing serum low density lipoprotein (LDL) level in a subject. The methods include inhibiting expression or function of an adenylate cyclase in the subject, wherein the inhibiting includes administration of an inhibitory nucleic acid molecule, such as an siRNA, to the subject.
Claims31
A method of decreasing serum low density lipoprotein (LDL) level in a subject, the method comprising inhibiting expression or function of an adenylate cyclase in the subject, wherein the inhibiting comprises administration of an inhibitory nucleic acid molecule to the subject.
A method of increasing LDL receptor expression in a subject, the method comprising inhibiting expression or function of an adenylate cyclase in the subject, wherein the inhibiting comprises administration of an inhibitory nucleic acid molecule to the subject.
An siRNA molecule comprising:
- (i) a sense strand comprising the sequence of SEQ ID NO:
- 3 and an antisense strand comprising the sequence of SEQ ID NO:
- 4;
- (ii) a sense strand comprising the sequence of SEQ ID NO:
- 5 and an antisense strand comprising the sequence of SEQ ID NO:
- 6;
- (iii) a sense strand comprising the sequence of SEQ ID NO:
- 7 and an antisense strand comprising the sequence of SEQ ID NO:
- 8;
- or
- (iv) a sense strand comprising the sequence of SEQ ID NO:
- 9 and an antisense strand comprising the sequence of SEQ ID NO:
- 10.
Use of an inhibitory nucleic acid molecule to decrease serum low density lipoprotein (LDL) level in a subject, wherein expression or function of an adenylate cyclase is inhibited in the subject by administration of an inhibitory nucleic acid molecule.
Use of an inhibitory nucleic acid molecule to decrease LDL receptor expression in a subject, wherein expression or function of an adenylate cyclase is inhibited in the subject by administration of an inhibitory nucleic acid molecule.
Dependencies are inferred from the claim text.